Choi et al developed an algorithm for using immunostains to subdivide patients with diffuse large B-cell lymphoma (DLBCL) into molecular subtypes. The authors are from multiple institutions in North America and Europe.
Subtypes of DLBCL:
(1) germinal center B-cell-like (GCB)
(2) activated B-cell-like (ABC)
Immunostains:
(1) GCET1 (germinal center B-cell expressed transcript 1)
(2) MUM1 (multiple myeloma oncogene 1
(3) CD10
(4) BCL6: (B cell lymphoma 6)
(5) FOXP1 (Forkhead box-P1)
The types determined by immunostains were compared with results of gene expression profiling (GEP).
|
GCET1 |
MUM1 |
CD10 |
BCL6 |
FOXP1 |
Type |
|
>= 80% |
>= 80% |
NA |
NA |
NA |
ABC |
|
>= 80% |
< 80% |
NA |
NA |
NA |
GCB |
|
< 80% |
NA |
>= 30% |
NA |
NA |
GCB (1) |
|
< 80% |
NA |
< 30% |
>= 30% |
>= 80% |
ABC (2) |
|
< 80% |
NA |
< 30% |
>= 30% |
< 80% |
GCB (3) |
|
< 80% |
NA |
< 30% |
< 30% |
NA |
ABC |
where:
• GCB(1): 1 of 12 cases classified ABC by GEP.
• ABC(2): 2 of 19 classified GCB by GEP.
• GCB(3): 3 of 10 clasified ABC by GEP.
• All others matched GEP.
Performance:
• The method (clone, source, antigen retrieval, instrument, analysis) is necessary to get the same results.
Specialty: Hematology Oncology
ICD-10: ,
